↓ Skip to main content

Short‐course versus long‐course therapy of the same antibiotic for community‐acquired pneumonia in adolescent and adult outpatients

Overview of attention for article published in Cochrane database of systematic reviews, September 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
26 X users
facebook
2 Facebook pages
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
218 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Short‐course versus long‐course therapy of the same antibiotic for community‐acquired pneumonia in adolescent and adult outpatients
Published in
Cochrane database of systematic reviews, September 2018
DOI 10.1002/14651858.cd009070.pub2
Pubmed ID
Authors

Jesús López‐Alcalde, Ricardo Rodriguez‐Barrientos, Jesús Redondo‐Sánchez, Javier Muñoz‐Gutiérrez, José María Molero García, Carmen Rodríguez‐Fernández, Julio Heras‐Mosteiro, Jaime Marin‐Cañada, Jose Casanova‐Colominas, Amaya Azcoaga‐Lorenzo, Virginia Hernandez Santiago, Manuel Gómez‐García

Abstract

Community-acquired pneumonia (CAP) is a lung infection that can be acquired during day-to-day activities in the community (not while receiving care in a hospital). Community-acquired pneumonia poses a significant public health burden in terms of mortality, morbidity, and costs. Shorter antibiotic courses for CAP may limit treatment costs and adverse effects, but the optimal duration of antibiotic treatment is uncertain. To evaluate the efficacy and safety of short-course versus longer-course treatment with the same antibiotic at the same daily dosage for CAP in non-hospitalised adolescents and adults (outpatients). We planned to investigate non-inferiority of short-course versus longer-term course treatment for efficacy outcomes, and superiority of short-course treatment for safety outcomes. We searched CENTRAL, which contains the Cochrane Acute Respiratory Infections Group Specialised Register, MEDLINE, Embase, five other databases, and three trials registers on 28 September 2017 together with conference proceedings, reference checking, and contact with experts and pharmaceutical companies. Randomised controlled trials (RCTs) comparing short- and long-courses of the same antibiotic for CAP in adolescent and adult outpatients. We planned to use standard Cochrane methods. Our searches identified 5260 records. We did not identify any RCTs that compared short- and longer-courses of the same antibiotic for the treatment of adolescents and adult outpatients with CAP.We excluded two RCTs that compared short courses (five compared to seven days) of the same antibiotic at the same daily dose because they evaluated antibiotics (gemifloxacin and telithromycin) not commonly used in practice for the treatment of CAP. In particular, gemifloxacin is no longer approved for the treatment of mild-to-moderate CAP due to its questionable risk-benefit balance, and reported adverse effects. Moreover, the safety profile of telithromycin is also cause for concern.We found one ongoing study that we will assess for inclusion in future updates of the review. We found no eligible RCTs that studied a short-course of antibiotic compared to a longer-course (with the same antibiotic at the same daily dosage) for CAP in adolescent and adult outpatients. The effects of antibiotic therapy duration for CAP in adolescent and adult outpatients remains unclear.

X Demographics

X Demographics

The data shown below were collected from the profiles of 26 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 218 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 218 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 38 17%
Student > Master 20 9%
Researcher 19 9%
Other 14 6%
Student > Postgraduate 14 6%
Other 35 16%
Unknown 78 36%
Readers by discipline Count As %
Medicine and Dentistry 71 33%
Nursing and Health Professions 24 11%
Pharmacology, Toxicology and Pharmaceutical Science 10 5%
Immunology and Microbiology 3 1%
Biochemistry, Genetics and Molecular Biology 3 1%
Other 19 9%
Unknown 88 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 July 2023.
All research outputs
#1,936,208
of 25,461,852 outputs
Outputs from Cochrane database of systematic reviews
#4,165
of 12,090 outputs
Outputs of similar age
#39,314
of 345,888 outputs
Outputs of similar age from Cochrane database of systematic reviews
#89
of 172 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,090 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.2. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,888 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 172 others from the same source and published within six weeks on either side of this one. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.